June 30, 2020
Daiichi Sankyo said on June 26 that a key European advisory panel has recommended against approval of its cancer drug pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT). The Japanese company submitted the drug...read more